SI3143011T1 - Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva - Google Patents

Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva

Info

Publication number
SI3143011T1
SI3143011T1 SI201531590T SI201531590T SI3143011T1 SI 3143011 T1 SI3143011 T1 SI 3143011T1 SI 201531590 T SI201531590 T SI 201531590T SI 201531590 T SI201531590 T SI 201531590T SI 3143011 T1 SI3143011 T1 SI 3143011T1
Authority
SI
Slovenia
Prior art keywords
heterocyclic compounds
imaging agents
deuterated
deuterated heterocyclic
imaging
Prior art date
Application number
SI201531590T
Other languages
English (en)
Inventor
Jan Marik
Joseph P. Lyssikatos
Simon Williams
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI3143011T1 publication Critical patent/SI3143011T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI201531590T 2014-05-13 2015-05-12 Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva SI3143011T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
EP15725253.7A EP3143011B1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents
PCT/EP2015/060447 WO2015173225A1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents

Publications (1)

Publication Number Publication Date
SI3143011T1 true SI3143011T1 (sl) 2021-08-31

Family

ID=53269446

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531590T SI3143011T1 (sl) 2014-05-13 2015-05-12 Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva

Country Status (21)

Country Link
US (4) US10076581B2 (sl)
EP (2) EP3901145A1 (sl)
JP (2) JP6529986B2 (sl)
KR (2) KR102530129B1 (sl)
CN (2) CN110483522B (sl)
AU (2) AU2015261008B2 (sl)
CA (1) CA2948721C (sl)
DK (1) DK3143011T3 (sl)
ES (1) ES2867814T3 (sl)
HR (1) HRP20210641T1 (sl)
HU (1) HUE053939T2 (sl)
IL (3) IL280791B2 (sl)
LT (1) LT3143011T (sl)
MX (2) MX2020010847A (sl)
PL (1) PL3143011T3 (sl)
PT (1) PT3143011T (sl)
RS (1) RS61810B1 (sl)
RU (1) RU2696492C2 (sl)
SG (2) SG10201805628TA (sl)
SI (1) SI3143011T1 (sl)
WO (1) WO2015173225A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3143011T (pt) 2014-05-13 2021-04-26 Hoffmann La Roche Compostos heterocíclicos deuterados e a sua utilização como agentes de imagiologia
MY196981A (en) 2016-07-22 2023-05-16 Ac Immune Sa Compounds for imaging tau protein aggregates
JP7059270B2 (ja) 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
KR102570992B1 (ko) * 2016-11-01 2023-08-28 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
WO2019145292A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
EP3758696A4 (en) 2018-03-02 2021-12-08 The Trustees of the University of Pennsylvania [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AND USE OF THESE IN THE STABILIZATION OF MICROTUBULES
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
CA3113233A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
EP3860989B1 (en) 2018-10-05 2023-04-05 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
FI3860998T3 (fi) 2018-10-05 2024-03-27 Annapurna Bio Inc Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
AU2020267664B2 (en) 2019-05-09 2023-04-27 F. Hoffmann-La Roche Ag Synthesis of labeled imidazo[1,2-A]pyrimidines
JP2022540935A (ja) 2019-07-17 2022-09-20 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化化合物および関連する使用方法
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
WO2023245008A1 (en) 2022-06-13 2023-12-21 Genentech, Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
DD76515A (sl) *
EP1340759A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
ATE539060T1 (de) 2006-03-30 2012-01-15 Univ Pennsylvania Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque
CA2698808A1 (en) * 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US8318132B2 (en) 2008-02-14 2012-11-27 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological dysfunction
US20100144657A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CN103739605B (zh) 2009-03-23 2016-08-17 伊莱利利公司 用于检测神经障碍的显像剂
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
KR20140003438A (ko) * 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
JP5976206B2 (ja) * 2012-05-22 2016-08-23 イーライ リリー アンド カンパニー 神経機能障害を検出するための造影剤
DK3055308T3 (en) * 2013-10-08 2018-01-22 Hoffmann La Roche Diazacarbazole derivatives as tau PET ligands
PT3143011T (pt) 2014-05-13 2021-04-26 Hoffmann La Roche Compostos heterocíclicos deuterados e a sua utilização como agentes de imagiologia

Also Published As

Publication number Publication date
MX2016014615A (es) 2017-03-06
KR20230035445A (ko) 2023-03-13
US10675367B2 (en) 2020-06-09
AU2015261008B2 (en) 2019-02-14
AU2019203369A1 (en) 2019-06-06
IL280791B1 (en) 2023-11-01
DK3143011T3 (da) 2021-05-03
EP3143011B1 (en) 2021-03-03
EP3143011A1 (en) 2017-03-22
KR102618139B1 (ko) 2023-12-27
BR112016026443A2 (pt) 2017-08-15
HRP20210641T1 (hr) 2021-05-28
CA2948721C (en) 2023-03-28
RU2016147742A3 (sl) 2018-10-08
CA2948721A1 (en) 2015-11-19
ES2867814T3 (es) 2021-10-20
JP2017515856A (ja) 2017-06-15
US20190201561A1 (en) 2019-07-04
LT3143011T (lt) 2021-05-10
IL248692A0 (en) 2017-01-31
SG11201609281UA (en) 2016-12-29
US10076581B2 (en) 2018-09-18
AU2015261008A1 (en) 2016-11-17
PL3143011T3 (pl) 2021-07-19
JP2019147825A (ja) 2019-09-05
HUE053939T2 (hu) 2021-08-30
NZ764181A (en) 2023-11-24
IL280791A (en) 2021-04-29
WO2015173225A1 (en) 2015-11-19
US20230218782A1 (en) 2023-07-13
KR102530129B1 (ko) 2023-05-10
CN110483522B (zh) 2022-05-03
US20200297875A1 (en) 2020-09-24
IL271631A (en) 2020-02-27
JP6681498B2 (ja) 2020-04-15
NZ726208A (en) 2023-11-24
MX2020010847A (es) 2021-07-16
PT3143011T (pt) 2021-04-26
IL248692B (en) 2020-01-30
CN110483522A (zh) 2019-11-22
AU2019203369B2 (en) 2020-06-04
RU2016147742A (ru) 2018-06-18
BR112016026443A8 (pt) 2021-07-06
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
KR20170002639A (ko) 2017-01-06
JP6529986B2 (ja) 2019-06-12
US20160250358A1 (en) 2016-09-01
RS61810B1 (sr) 2021-06-30
US11504440B2 (en) 2022-11-22
CN106459059A (zh) 2017-02-22
EP3901145A1 (en) 2021-10-27
CN106459059B (zh) 2019-09-24
IL271631B (en) 2021-05-31
IL280791B2 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
IL248692B (en) Heterocyclic compounds containing deuterium and their use as imaging agents
HK1244000B (zh) 多環氨基甲酰吡啶酮化合物及其藥物用途
GB201403093D0 (en) Therapeutic compounds and their use
IL264258B (en) Diazahetero-bicyclic substituted compounds and their use
HK1232137A1 (zh) 治療化合物和組合物
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
ZA201701312B (en) Novel imidazopyridazine compounds and their use
IL247599B (en) Formulation that suppresses the immune system
PT3268356T (pt) Compostos heterocíclicos e métodos para a sua utilização
PL3129398T3 (pl) Nowe środki medyczne i ich zastosowanie
GB201420506D0 (en) Fresh "N" up
GB201613134D0 (en) Novel compounds and their use
GB201514770D0 (en) Compounds and their use
GB201513318D0 (en) Novel compounds and their use
GB201413411D0 (en) Novel compounds and their use
GB201420795D0 (en) Super sponge
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use
GB201411907D0 (en) Targeted imaging agent